Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
Juan Bautista Blaquier, Gonzalo Recondo
Abstract
In this article, the authors focus on the management of patients with MET exon 14 skipping alterations by addressing the biology of the MET receptor and exon 14 skipping mutations, current treatment strategies, and sequential treatment options based on resistance mechanisms to MET inhibitors in patients with non-small-cell lung cancer.
Topics & Concepts
ExonReceptor tyrosine kinaseCancer researchTyrosine kinaseLung cancerMedicineTargeted therapyMAPK/ERK pathwayProtein kinase BPI3K/AKT/mTOR pathwayCancerBiologySignal transductionOncologyInternal medicineReceptorGeneticsGeneLiver physiology and pathologyLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer